Φορτώνει......
p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer
Administration of the microtubule inhibitor docetaxel is a common treatment for metastatic castration-resistant prostate cancer (mCRPC) and results in prolonged patient overall survival. Usually, after a short period of time chemotherapy resistance emerges and there is urgent need to find new therap...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Endocr Relat Cancer |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Bioscientifica Ltd
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7040497/ https://ncbi.nlm.nih.gov/pubmed/31951590 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-19-0488 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|